Business Context and Reporting Period
Company: Psyence Biomedical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 5, 2024
Reporting Period: Month of September 2024
Principal Executive Office: Toronto, Ontario, Canada
The filing discloses the entry into a strategic license agreement on September 3, 2024, with Psyence UK Group Ltd. ("Psylabs") to advance the development of psychedelic active pharmaceutical ingredients (APIs) for alcohol use disorder and substance use disorder.
Key Financial Metrics and Obligations
This filing details contractual financial obligations rather than historical financial performance. No revenue, profit, cash flow, or balance sheet data is provided in this document.
| Payment Type | Trigger Event | Amount (USD) |
|---|---|---|
| Development Milestone | July 31, 2026 or approval to commence trial (whichever is earlier) | $73,000 per Field of Use |
| Development Milestone | Delivery of fully formulated licensed product | $75,000 per Field of Use |
| Commercial Milestone | Submission and approval of Phase III clinical trial application | $292,000 per Phase III trial |
| Commercial Milestone | First marketing approval permitting commercial sales | $584,000 per Field of Use |
| Commercial Milestone | Each subsequent marketing approval | $292,000 per Field of Use |
| Annual Fee | Commencing on Phase II clinical trial study report date | $146,000 per year per Field of Use |
| Royalty Fee | Commencing upon first commercial sale | 10% of net sales |
Material Changes
The primary material change is the execution of the License Agreement with Psylabs, granting Psyence Biomedical exclusive, worldwide, royalty-bearing licenses for:
- Conducting clinical trials and commercializing development.
- Extraction, formulation, and licensing of proprietary psilocybin standardized extract (API).
- Final dosage formats suitable for human consumption.
- Specific Fields of Use: Alcohol use disorder and substance use disorder.
The Company retains the right to sub-license the products subject to restrictions.
Outlook, Risks, and Contingencies
Exclusivity Conditions: The exclusive licenses may expire if:
- The Company fails to make commercially reasonable efforts to commence trials by December 31, 2026.
- The Company fails to pay a minimum of $73,000 in Royalty Fees per calendar year starting January 1, 2030.
Payment Terms: Royalty fees are calculated quarterly and payable in arrears within 30 days. The annual fee of $146,000 is creditable against the Royalty Fee.
Risk Factors: The agreement contains customary representations, warranties, and indemnification obligations. The filing notes that the description provided is not complete and is subject to the full text of the agreement filed as Exhibit 99.1.
Investor Verification Checklist
- Exhibit 99.1: Review the full text of the License Agreement for detailed covenants and limitations not summarized here.
- Exhibit 99.2: Consult the press release issued on September 4, 2024, for additional context on the Purchase Agreement terms.
- Financial Capacity: Verify the Company's current liquidity to meet the $73,000 development milestone due by July 31, 2026, or upon trial approval.
- Regulatory Status: Confirm the timeline for Phase II clinical trial study reports, as this triggers the start of the $146,000 annual fee.
- Sub-licensing Rights: Assess the specific restrictions on sub-licensing mentioned in the agreement.